Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 9/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Artemotil SCHEMBL16710281 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL17156474 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL16404848 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL341227 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL60335 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL18422062 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL10041607 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL60336 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL4539927 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 | |
| Artemotil SCHEMBL18950949 | 1.00 | PTGES2 (0.76) | PTGES2LMNAHTTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1264508-C | Arteannuin preparation for treating gynecopathy | KUNMING ZIJIAN BIOTECHNOLOGY C (CN) | 2006-07-19 | — | — | CN | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4698580-A1 | CROSSLINKABLE COMPOSITIONS BASED ON SILANE-CROSSLINKING ORGANIC POLYMERS WITH HIGH THERMAL CONDUCTIVITY | Wacker Chemie AG (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2024217693-A1 | CROSSLINKABLE COMPOSITIONS BASED ON SILANE-CROSSLINKING ORGANIC POLYMERS WITH HIGH THERMAL CONDUCTIVITY | WACKER CHEMIE AG (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | disclosed |
| CN-118697728-A | Application of artemisinin derivative in preparation of medicine for improving binding capacity of LONP protein and substrate thereof | 复旦大学附属中山医院 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| US-11739064-B2 | HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-08-29 | — | — | US | disclosed |
| CN-108354927-A | The new pharmaceutical uses of arteether | 上海壹志医药科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-9801851-B2 | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-31 | — | — | US | disclosed |
| US-9603831-B2 | Artemisinin and its derivatives for use in the treatment of kidney disease | QUEEN MARY & WESTFIELD COLLEGE, UNIVERSITY OF LONDON (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-14 | — | — | US | disclosed |
| CN-102485226-B | Compound artemisinin piperaquine pellet and preparation method thereof | KUNMING PHARMACEUTICAL GROUP | 2013-06-05 | — | — | CN | disclosed |
| CN-102485226-A | Compound artemisinin piperaquine pellet and preparation method thereof | KUNMING PHARMACEUTICAL GROUP | 2012-06-06 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-1264508-C | Arteannuin preparation for treating gynecopathy | KUNMING ZIJIAN BIOTECHNOLOGY C (CN) | 2006-07-19 | — | — | CN | disclosed |
| CN-1602858-A | Arteannuin preparation for treating gynecopathy | KUNMING ZIJIAN BIOTECHNOLOGY C (CN) | 2005-04-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | PTGES2 4831/4885LMNA 952/4885HTT 3233/4885 |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | PTGES2 4451/4885LMNA 1031/4885HTT 1047/4885 |
| US-20150133462-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS | ABL1, BCR, ABL2 | PTGES2 3137/4885LMNA 2499/4885HTT 2517/4885 |
| US-11739064-B2 | HDAC inhibitors and therapeutic methods using the same | HDAC1, HDAC9, HDAC8 | PTGES2 3987/4885LMNA 2543/4885HTT 134/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | PTGES2 4451/4885LMNA 1031/4885HTT 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.